Lack of a chemobrain effect for adjuvant FOLFOX chemotherapy in colon cancer patients. A pilot study

Andreis, Federica; Ferri, Marco; Mazzocchi, Maria; Meriggi, Fausto; Rizzi, Anna; Rota, Luigina; Biasi, Brunella Di; Abeni, Chiara; Codignola, Claudio; Rozzini, Renzo; Zaniboni, Alberto

doi:10.1007/s00520-012-1560-2

Cited by 28 publications

(11 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MMSE test has been used in breast cancer studies to measure dementia (43,44), global cognitive functioning (19), or chemotherapy-and radiotherapy-related cognitive deterioration (45,46). The CDT is a commonly used tool for detecting cognitive deficiency also in cancer patients (47)(48)(49)(50). The depression and anxiety tests, like BDI (12,13,17,40), HDRS (51), STAI-S and STAI-T (6,17,24,40) have been extensively utilized in breast cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Cognitive Functioning and Psychological Well-being in Breast Cancer Patients on Endocrine Therapy

Biró

Kahán

Kálmán

et al. 2019

In Vivo

View full text Add to dashboard Cite

Background/Aim: Anti-cancer therapies may deteriorate cognitive functioning, affective functioning and psychological well-being. Materials and Methods: In this prospective longitudinal pilot study, premenopausal and postmenopausal patients received adjuvant endocrine therapy (ET) (tamoxifen with or without LHRH analog or aromatase inhibitor) or were observed only (control group). At baseline testing and 6, 12 and 24 months thereafter, cognitive, depression and anxiety tests and quality of life (QOL) measurements were performed. Results: Overall, 46 cases were evaluated. None of the studied cognitive parameters differed between the subgroups or changed by time. No differences were found regarding anxiety, depression or QOL measures either. Baseline cognitive test and QOL results were in association with later anxiety and depression. Conclusion: No cognitive impairment was found during the two years of ET. Baseline cognitive scores and QOL dimensions proved good predictors of later anxiety and depression.

show abstract

Section: Discussionmentioning

confidence: 99%

Cognitive Functioning and Psychological Well-being in Breast Cancer Patients on Endocrine Therapy

Biró

Kahán

Kálmán

et al. 2019

In Vivo

View full text Add to dashboard Cite

show abstract

“…One reported no cognitive impairment but was limited by small sample size, lack of a comparator group, use of a brief cognitive battery, and failure to account for practice effect. 6 The other study reported 37% to 39% cognitive impairment before and 6 months after chemotherapy, with a decline from baseline in 52% of participants, particularly in verbal memory. 7 We recently published baseline data from a prospective longitudinal study evaluating cognitive function in patients with CRC, which showed that 43% had objective cognitive impairment shortly after diagnosis, compared with 15% in healthy controls (HCs) without cancer.…”

Section: Introductionmentioning

confidence: 92%

Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study

Vardy

Dhillon

Pond

et al. 2015

JCO

213

142

View full text Add to dashboard Cite

Purpose Cognitive dysfunction is reported in people with cancer. Therefore, we evaluated longitudinal changes in cognitive function and underlying mechanisms in people with colorectal cancer (CRC) and healthy controls (HCs). Patients and Methods Participants completed cognitive assessments and questionnaires reporting cognitive symptoms, fatigue, quality of life, and anxiety/depression at baseline (before chemotherapy, if given) and 6, 12, and 24 months. Blood tests included cytokines, clotting factors, apolipoprotein E genotype, and sex hormones. Primary end point was overall cognitive function measured by the Global Deficit Score at 12 months. Results We recruited 289 patients with localized CRC (173 received chemotherapy; median age, 59 years; 63% male), 73 patients with limited metastatic/recurrent CRC, and 72 HCs. Cognitive impairment was more frequent in patients with localized CRC than HCs at baseline (43% v 15%, respectively; P < .001) and 12 months (46% v 13%, respectively; P < .001), with no significant effect of chemotherapy. Attention/working memory, verbal learning/memory, and complex processing speed were most affected. Cognitive impairment was similar in patients with localized and metastatic CRC. Cytokine levels were elevated in patients with CRC compared with HCs. There was no association between overall cognitive function and fatigue, quality of life, anxiety/depression, or any blood test. Cognitive symptoms at 12 months were reported in 25% of patients with localized CRC versus 17% of HCs (P = .19). More participants who received chemotherapy had cognitive symptoms at 6 months (32%) versus those who did not (16%; P = .007), with no significant difference at 12 months (29% v 21%, respectively; P = .19). Objective cognitive function was only weakly associated with cognitive symptoms. Conclusion Patients with CRC had substantially more cognitive impairment at every assessment than HCs, with no significant added effect of chemotherapy. Mechanisms of cognitive impairment remain unknown.

show abstract

“…This confirms hypothesis 4, that everyday problem solving ability and cognitive functioning are related. (Andreis, Ferri, Mazzocchi, Meriggi, Rizzi, Rota, et al, 2012). Thus it is possible that CRCI simply does not exist in this patient group.…”

Section: Emotional Functioningmentioning

confidence: 88%

The Effect of Chemotherapy on Cognition in Patients Treated for Colorectal Cancer

Hodgson¹,

Wilson²,

Hutchinson³

et al. 2013

ACRT

View full text Add to dashboard Cite

Chemotherapy-related cognitive impairment (CRCI) is commonly reported following the administration of chemotherapy to cancer patients, with most confirmatory results obtained from the cohort of breast cancer patients. The aims of the present study were to assess whether CRCI is consistently observed in people treated for colorectal cancer, to assess the impact of different treatment regimens, and to identify the domains of cognition affected.This study comprised four sample groups, three of which had been diagnosed and treated for colorectal cancer; chemotherapy patients (n = 19), patients treated with chemotherapy and the anti-angiogenic drug Avastin TM (n = 12), and surgery only patients (n = 10). A fourth, comparably aged and educated healthy control group was also included (n = 20). Each participant undertook approximately 90 minutes of testing, comprising nine neuropsychological tests, including a measure of everyday problem solving and self-report measures of anxiety, fatigue, depression and cognition.Multivariate analysis of variance revealed no significant differences between the groups across the neuropsychological test total scores. However, a significant difference was found when those tests comprised of subscales were broken down into their components; comparison between the surgery and healthy control groups found a difference on the delayed recall component of the logical memory test, with the surgery group having performed more poorly. Significant relationships were found between years of education, premorbid ability and everyday problem solving ability and cognitive functioning. The current study identified no significant increase in cognitive impairment related to chemotherapy and anti-angiogenic drugs used to treat colorectal cancer.

show abstract

Lack of a chemobrain effect for adjuvant FOLFOX chemotherapy in colon cancer patients. A pilot study

Cited by 28 publications

References 30 publications

Cognitive Functioning and Psychological Well-being in Breast Cancer Patients on Endocrine Therapy

Cognitive Functioning and Psychological Well-being in Breast Cancer Patients on Endocrine Therapy

Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study

The Effect of Chemotherapy on Cognition in Patients Treated for Colorectal Cancer

Contact Info

Product

Resources

About